BUSINESS

Eisai Aims for US Accelerated OK for Lecanemab in 2022; Japan/EU Filing Planned by March 2023

February 4, 2022

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Eisai hopes to clinch accelerated approval for its Alzheimer’s drug lecanemab in the US by the end of this year, with its rolling submission making good headway and expected to wrap up earlier than planned, the company’s neurology business chief…

To read the full story

Lecanemab Scores Positive Results in PIIb Study: Eisai/Biogen
March 23, 2022
Eisai Begins Data Submission for Lecanemab for Swift Approval in Japan
March 7, 2022

BUSINESS

Eisai CFO Casts Oncology Pipeline Expansion as Urgent Task
February 10, 2026
Pharma Fears Off-Year Price Reform Loses Traction after LDP Sweep
February 10, 2026
Chugai’s Hemlibra Successor Shows Promise in PI/II Study
February 10, 2026
Leqembi Subcutaneous Autoinjector Gets Priority Review in China
February 10, 2026
Leqembi Global Sales Hit 61.8 Billion Yen in April-December: Eisai
February 9, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key

By Sakura Kono

Japan is poised to make the most sweeping revision in eight years to the Standards for Biological Raw Materials —…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…